SEC Form 4 · accession 0001179110-18-014215
Tabula Rasa HealthCare, Inc. · TRHC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Orsula V Knowlton
Officer — President · Director
Period of report
Dec 18, 2018
Accepted (ET)
Dec 21, 2018 · 8:15 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001651561
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Dec 18, 2018 | S | 3,200 | $62.74 | D | 837,461 | D | |
| Common StockF3 | Dec 18, 2018 | S | 1,800 | $63.62 | D | 835,661 | D | |
| Common StockF4 | Dec 18, 2018 | S | 3,000 | $64.58 | D | 832,661 | D | |
| Common Stock | holding | — | — | — | 848,129 | I | Held by spouse. |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2018.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $62.11 to $63.09, inclusive. The reporting person undertakes to provide to Tabula Rasa HealthCare, Inc., any security holder of Tabula Rasa HealthCare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $63.11 to $64.06, inclusive.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $64.15 to $65.08, inclusive.
- F5The sales aggregated in Row 2 of Table I are not matchable under Section 16(b) of the Securities Exchange Act of 1934 against purchases at lower prices by Dr. Calvin H. Knowlton on November 12, 2018 because such purchases were previously matched with sales on September 7, 2018 at higher sales prices, and Dr. Calvin H. Knowlton has already paid to Tabula Rasa Healthcare, Inc. the full amount of profit realized in connection with the previous short-swing transactions. Thus, no further disgorgement under Section 16(b) would result from the transactions disclosed herein.
- F6The sales aggregated in Row 3 of Table I are not matchable under Section 16(b) of the Securities Exchange Act of 1934 against purchases at lower prices by Dr. Calvin H. Knowlton on November 12, 2018 because such purchases were previously matched with sales on September 7, 2018 at higher sales prices, and Dr. Calvin H. Knowlton has already paid to Tabula Rasa Healthcare, Inc. the full amount of profit realized in connection with the previous short-swing transactions. Thus, no further disgorgement under Section 16(b) would result from the transactions disclosed herein.